Published in J Nucl Med on June 12, 2009
Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies. J Nucl Med (2010) 1.45
Molecular pathways: targeted α-particle radiation therapy. Clin Cancer Res (2012) 1.24
Astatine-211: production and availability. Curr Radiopharm (2011) 1.12
Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol (2011) 1.10
Cancer radioimmunotherapy. Immunotherapy (2011) 1.10
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm (2013) 1.05
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. Curr Radiopharm (2011) 1.04
Transcriptional response of BALB/c mouse thyroids following in vivo astatine-211 exposure reveals distinct gene expression profiles. EJNMMI Res (2012) 0.98
A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry. Phys Med Biol (2012) 0.97
A high-throughput screen for alpha particle radiation protectants. Assay Drug Dev Technol (2010) 0.95
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis. Eur J Nucl Med Mol Imaging (2012) 0.93
Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice. J Oncol (2009) 0.92
Alpha particles induce apoptosis through the sphingomyelin pathway. Radiat Res (2011) 0.91
The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol (2014) 0.90
Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med (2014) 0.89
The elements of life and medicines. Philos Trans A Math Phys Eng Sci (2015) 0.88
A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters? Pharmaceuticals (Basel) (2015) 0.88
Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther (2013) 0.88
In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. Eur J Nucl Med Mol Imaging (2010) 0.87
Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One (2013) 0.87
Emerging trends for radioimmunotherapy in solid tumors. Cancer Biother Radiopharm (2013) 0.86
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin Biol Ther (2016) 0.85
Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy. Cancer Biother Radiopharm (2012) 0.83
Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl Med Biol (2013) 0.83
Transcriptional response in normal mouse tissues after i.v. (211)At administration - response related to absorbed dose, dose rate, and time. EJNMMI Res (2015) 0.83
Tumor immunotargeting using innovative radionuclides. Int J Mol Sci (2015) 0.82
Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest. Eur J Nucl Med Mol Imaging (2012) 0.82
Modelling and dosimetry for alpha-particle therapy. Curr Radiopharm (2011) 0.81
Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation. PLoS One (2013) 0.81
Gene expression signature in mouse thyroid tissue after (131)I and (211)At exposure. EJNMMI Res (2015) 0.80
Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention. Bioconjug Chem (2011) 0.79
Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy. Radiat Res (2014) 0.78
Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis. Front Med (Lausanne) (2015) 0.78
Application of (212)Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. AIMS Med Sci (2015) 0.78
Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200. PLoS One (2015) 0.78
Transcriptional Response in Mouse Thyroid Tissue after 211At Administration: Effects of Absorbed Dose, Initial Dose-Rate and Time after Administration. PLoS One (2015) 0.78
Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model. Front Med (Lausanne) (2015) 0.76
Systemic targeted alpha radiotherapy for cancer. J Biomed Phys Eng (2013) 0.76
Targeted alpha anticancer therapies: update and future prospects. Biologics (2014) 0.76
Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the (213)Bi-labeled monoclonal antibody MX35 in an ovarian cancer model. EJNMMI Res (2017) 0.75
Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer (2017) 0.75
Targeting Prostate Cancer Stem Cells with Alpha-Particle Therapy. Front Oncol (2017) 0.75
Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies. Cancer Biother Radiopharm (2015) 0.75
Surgical immune interventions for solid malignancies. Am J Surg (2016) 0.75
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for (211)At labeling at high activities and radiation doses of (211)At α-particles. Nucl Med Biol (2016) 0.75
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb. EJNMMI Res (2013) 0.75
B7-H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol (2017) 0.75
Pharmacodynamic study of (131)I-labeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer. Exp Ther Med (2015) 0.75
Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. ScientificWorldJournal (2014) 0.75
Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials. Sci Rep (2015) 0.75
Validating α-particle emission from 211At-labeled antibodies in single cells for cancer radioimmunotherapy using CR-39 plastic nuclear track detectors. PLoS One (2017) 0.75
Locoregional therapy with α-emitting trastuzumab against peritoneal metastasis of HER2-positive gastric cancer in mice. Cancer Sci (2017) 0.75
mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res (2006) 2.76
Reducing stigma and discrimination against older people with mental disorders: a technical consensus statement. Int J Geriatr Psychiatry (2003) 2.35
Stunning of iodide transport by (131)I irradiation in cultured thyroid epithelial cells. J Nucl Med (2002) 2.16
The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med (2012) 1.84
Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med (2006) 1.75
Five-year mortality in a cohort of people with schizophrenia in Ethiopia. BMC Psychiatry (2011) 1.66
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med (2010) 1.61
Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res (2004) 1.38
[Reconsider the diagnosis and treatment approach for ADHD]. Lakartidningen (2015) 1.38
Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A (2011) 1.29
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab (2007) 1.25
Development of a questionnaire on attitudes towards suicide (ATTS) and its application in a Swedish population. Suicide Life Threat Behav (2003) 1.23
Community-based mental health care in Africa: mental health workers' views. World Psychiatry (2008) 1.22
Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Int J Radiat Oncol Biol Phys (2007) 1.21
Current status of therapy of solid tumors. J Nucl Med (2005) 1.14
The alpha-camera: a quantitative digital autoradiography technique using a charge-coupled device for ex vivo high-resolution bioimaging of alpha-particles. J Nucl Med (2010) 1.13
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol (2005) 1.13
Liposarcoma: outcome based on the Scandinavian Sarcoma Group register. Cancer (2008) 1.11
Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer (2006) 1.10
Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys (2007) 1.09
Spinal CSF absorption in healthy individuals. Am J Physiol Regul Integr Comp Physiol (2004) 1.04
A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med (2002) 1.04
Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer (2008) 1.03
External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study. Int J Radiat Oncol Biol Phys (2011) 1.01
Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. J Nucl Med (2005) 1.00
Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers. BMC Psychiatry (2013) 0.99
Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage. Genes Chromosomes Cancer (2004) 0.98
Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res (2003) 0.98
Prolonged red cell storage before transfusion increases extravascular hemolysis. J Clin Invest (2016) 0.97
Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model. Nucl Med Biol (2011) 0.97
A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. Int J Gynecol Cancer (2009) 0.96
Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate. J Nucl Med (2008) 0.95
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas. BMC Cancer (2009) 0.95
Depression and anxiety in the reindeer-herding Sami population of Sweden. Int J Circumpolar Health (2010) 0.95
Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice. Cancer Biother Radiopharm (2009) 0.94
ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J Pharm Sci (2008) 0.94
Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cancer Genet Cytogenet (2005) 0.93
Regional collaboration in reconstruction of mental health services in Bosnia and Herzegovina. Psychiatr Serv (2005) 0.93
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int J Cancer (2009) 0.92
Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging (2010) 0.92
Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice. J Oncol (2009) 0.92
Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. Nucl Med Biol (2006) 0.92
Suicide and suicide attempts in people with severe mental disorders in Butajira, Ethiopia: 10 year follow-up of a population-based cohort. BMC Psychiatry (2014) 0.92
Public awareness and attitudes towards epilepsy in Tehran, Iran. Glob Health Action (2013) 0.91
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels. J Thorac Oncol (2007) 0.91
Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence in situ hybridization. Cancer Genet Cytogenet (2008) 0.91
Irradiation of myxoid/round cell liposarcoma induces volume reduction and lipoma-like morphology. Acta Oncol (2007) 0.91
Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review. World J Nucl Med (2011) 0.90
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood (2011) 0.89
Community attitudes towards epilepsy in a rural Ethiopian setting: a re-visit after 15 years. Ethiop Med J (2008) 0.89
211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo. J Nucl Med (2005) 0.89
Ex vivo activity quantification in micrometastases at the cellular scale using the α-camera technique. J Nucl Med (2013) 0.88